Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)

Market Cap	4.54B -0.7%
Revenue (ttm)	2.47B +3.2%
Net Income	16.84M
EPS	0.03
Shares Out	438.41M
PE Ratio	269.49
Forward PE	35.69
Dividend	0.30 (2.90%)
Ex-Dividend Date	Jun 4, 2026

Volume	21,179,187
Open	10.31
Previous Close	10.38
Day's Range	10.05 - 10.50
52-Week Range	8.97 - 14.37
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About SHA:603520

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadobenate dimeglumine injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, ioversol, iopromide, iomeprol, gadobenat...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 1,905
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603520

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error